Related Experiment Videos
[Usefulness of perospirone for the prevention of nausea related to opioid administration]
Kinomi Yomiya1, Naoki Matsuo, Shinichirou Okuyama
1Department of Palliative Care, Saitama Cancer Center.
Purpose:
In our department, prochlorperazine, a D2 receptor antagonist, was previously administered to prevent nausea related to the introduction of opioids. However, we always had to consider extrapyramidal symptoms. Since August 2006, perospirone has been administered to all patients who have commenced oral opioid therapy, to prevent nausea. In this study, we investigated its usefulness in the prevention of nausea.
Methods:
Perospirone (4 or 8 mg, once a day) was combined in all patients in whom opioid therapy was introduced with oxycodone at 10 mg/day. We retrospectively examined the presence or absence of nausea within 1 week.
Results:
Oxycodone-related nausea occurred in 1 of 25 patients. There were no adverse reactions such as extrapyramidal symptoms.
Conclusion:
These results suggest the usefulness of perospirone for the prevention of nausea related to the intro- duction of opioids.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...